Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Potential Therapeutic Effects of Apigenin for Colorectal Adenocarcinoma: A Systematic Review and Meta-Analysis Publisher Pubmed



Ahmadzadeh K1 ; Roshdidizaji S1 ; Ramezani F1 ; Imani F2 ; Shamseddin J3 ; Sarveazad A4, 5 ; Yousefifard M1, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Pain Research Center, Department of Anesthesiology and Pain Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
  4. 4. Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Pediatric Chronic Kidney Disease Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Cancer Medicine Published:2024


Abstract

Purpose: Therapeutic management of colorectal cancer (CRC) does not yet yield promising long-term results. Therefore, there is a need for further investigation of possible therapeutic options. Various experiments have studied the effects of apigenin on CRC and have shown conflicting results. This systematic review and meta-analysis investigates the currently existing evidence on the effect of apigenin on CRC. Methods: Medline, Embase, Scopus, and Web of Science databases were searched for articles related to apigenin and its effect on CRC in the preclinical setting. Cell viability, growth inhibition, apoptosis, and cell cycle arrest for in-vitro, and body weight, tumor size, and mortality in in-vivo studies were extracted as outcomes. Results: Thirty-nine articles investigating colorectal adenocarcinoma were included in this meta-analysis. Thirty-seven of these studies had data for in vitro experiments, with eight studies having data for in vivo experiments. Six articles had both in vitro and in vivo assessments. Our analysis showed apigenin reduces cell viability and induces growth inhibition, apoptosis, and cell cycle arrest in in vitro studies. The few in vivo studies indicate that apigenin decreases tumor size while showing no effects on the body weight of animal colorectal adenocarcinoma models. Conclusion: Our results demonstrated that apigenin, through reducing cell viability, inducing growth inhibition, apoptosis, and cell cycle arrest, and also by decreasing the tumor size, can be considered as a possible adjuvant agent in the management of colorectal adenocarcinoma. However, further in vivo studies are needed before any efforts to translate the current evidence into clinical studies. © 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.